Sichuan Kelun-Biotech Biopharmaceutical
Pre-Approval PRO BETAPipeline by Phase
Therapeutic Focus
Clinical Trials (54)
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Started: 2/28/2024
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
Started: 7/18/2025
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Started: 10/31/2023
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial
Started: 3/18/2018
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Started: 6/7/2024
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Started: 11/27/2024
A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
Started: 7/18/2023
Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC
Started: 12/31/2020
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Started: 6/26/2023
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Started: 6/7/2022
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Started: 6/10/2022
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Started: 10/30/2024
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Started: 5/20/2022
A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors
Started: 4/8/2026
A Phase II Study of SKB571 in Patients With Lung Cancer
Started: 1/19/2026
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Started: 3/30/2026
A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
Started: 4/3/2026
A Study of SKB571 in Participants With Gastrointestinal Tumors
Started: 5/20/2026
SKB500 Combinations in Patients With Small Cell Lung Cancer
Started: 1/30/2026
A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
Started: 9/20/2024
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
Started: 3/13/2026
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
Started: 7/15/2026
A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants
Started: 7/27/2026
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
Started: 8/13/2026
SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
Started: 8/7/2026
A Study of KL130008 in Adults With Severe Alopecia Areata
Started: 11/9/2022
Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC
Started: 1/16/2026
SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
Started: 11/30/2022
SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer
Started: 8/17/2022
KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma
Started: 3/6/2019
An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma
Started: 8/1/2018
SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ Adenocarcinoma
Started: 6/30/2026
A Multicenter, Open-label, Phase II Umbrella Study to Evaluate the Efficacy and Safety of the Investigational Product in Participants With Advanced or Metastatic Pancreatic Cancer
Started: 10/31/2026
A Study of SKB107 in Advanced Solid Tumors With Bone Metastases
Started: 8/15/2025
A Study of SKB518 in Patients With Advanced Solid Tumors
Started: 7/4/2024
A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors
Started: 12/17/2024
A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants
Started: 3/31/2026
A Study of SKB315 in Patients With Advanced Solid Tumors
Started: 3/16/2022
A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors
Started: 12/13/2024
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-6204 (SKB535) for Injection in Participants With Advanced Solid Tumors
Started: 12/12/2024
A Randomized, Phase Ib, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SKB575 (HBM7575) in Participants With Asthma
Started: 8/25/2026
Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer
Started: 12/30/2016
A Study of Intratumoral KL340399 in Patients With Advanced Solid Tumors
Started: 8/30/2022
A Study of KL340399 in Patients With Advanced Solid Tumors
Started: 6/7/2022
A Study of KL590586 in Patients With Advanced Solid Tumors
Started: 9/15/2021
A Study of A166 in Patients With Advanced Solid Malignant Tumors
Started: 8/9/2018
Study of SKB103 in HER2-negative Breast Cancer
Started: 8/31/2026